Dry eye treatment Phase III study

Article

A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.

A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.

Resolvyx Pharmacuticals' RX-10045 is a resolvin that will be administered as a topical eye drop. In a large Phase II placebo-controlled study it was found that the eye drop produced dose-dependent, improvement on the primary endpoints for both signs and symptoms of dry eye, and was shown to be safe and well-tolerated.

Resolvins have demonstrated high potency and efficacy in the treatment of dry eye and retinal disease as well as asthma, rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.

Stephen Evans-Freke and Peter B Corr, co-founders and Managing General Partners of Celtic Therapeutics Holdings, said: "We look forward to a close and successful alliance with Resolvyx to optimize the medical potential and financial returns from this exciting class of novel anti-inflammatory molecules in the ophthalmology field. If approved, RX-10045 should provide superior efficacy to current therapeutic options in dry eye. We are eager to explore the activity of resolvins in additional ophthalmic indications as well."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.